We recently published a list of the 15 best growth shares to buy over the next 3 years. In this article, let’s take a look where Eli Lilly and Company (Nyse: Lly) is against other growth shares to buy for the next 3 years.
On April 29, Dan Ives from Wedbush Securities joined “Power Lunch” at CNBC to discuss his perspective on the technology sector, and stated that the rates did not stop the AI revolution. According to Ives, the critical issue for the sector was if the expense was maintained, particularly Capex. He expressed his confidence that CAPEX maintained and predicted that the coming results of large technology companies would serve as a trusted reinforcer for the market, instead of feeding existing fears. As some investors are about the idea that they care about the potential patch of the economy, there is a preference for more safe investments in insurance and other stable sectors, instead of great technologies. However, Ives acknowledged that, while uncertainty has been predominant in recent weeks, his own poll work and field research indicate that AI -related expense remains strong. He said that although there were areas in the cloud sector where spending was accelerated, overall uncertainty could lead to broad business orientations.
Michael Darda, the CEO, chief economist and macrostrategist of Roth, also believes that the AI would generate solid returns in the future. Ives agreed with Darda’s evaluation and stated that companies were seeing similar advances and could not afford their AI projects without the risk of falling accordingly. He also said that for companies like Mag7, the AI revolution is a central theme, so the challenges posed by the rates would not affect the AI revolution so much. Darda changed his perspective as Bearish in Bullish where Tech and Ai recently due to his personal experience with Ai Tools, which he considered to have improved for the last year.
Dan Ives reiterated that, despite the uncertainty created by the rates, the demand for software remained a safety blanket and the expense of the hyper -skewed companies is expected to continue.
We took advantage of financial media reports to collect a list of higher growth stocks to buy for the next 3 years. Then we selected 15 shares with an annual growth rate of 3 -year compounds over 20%. Stocks are classified in ascending order of the number of coverage funds, from the fourth quarter of 2024, which was obtained from the database Insider Monkey.
Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (sEE More details here)).
Eli Lilly and Co. (NYSE: Lly) Is the best growth stock to buy for the next 3 years?
A series of pharmaceutical tablets with the company logo in l’Ampolla.
3 Years CAGR Income: 16.73%
Number of coverage fund holders: 115
Eli Lilly and Company (NYSE: Lly) Discover, develop and sell human pharmacists. The company’s portfolio includes treatments for diabetes, obesity, oncology, autoimmune diseases and neurological conditions. It attends patients to all the United States and internationally through different collaborations and collaborations.
Eli Lilly and Company (NYSE: Lly) entry into the GLP-1 space has been very successful, which stands out for the recent rehearsal of Phase 3 of Orfliverglpron. This is an GLP-1 oral agonist. The ASSEP-1 Type 2 diabetes trial showed A1C reductions from 1.3% to 1.6% from a reference line of 8.0%, with a placebo that showed a reduction of 0.1%. Eli Lilly and Company (NYSE: Lly) plans to present OrForglprgron for the approval of obesity treatment at the end of 2025 and for type 2 diabetes in 2026.
The company has also been in an acquisition in recent years. Eli Lilly bought 8 companies and signed 3 new collaborations. These movements, based on Dice Therapeutics in the mid -2013 and more recently Therapeutics Scorpion by the beginning of 2025, helped the company grow in new areas. On April 21, Evan Seigerman, by BMO Capital, maintained a purchase rating at Eli Lilly with a $ 900 price goal due to his strong position in the pharmaceutical industry.
Parnassus Core Equity Fund considers Eli Lilly and Co. (NYSE: Lly) as a strong long-term investment due to its GLP-1 franchise and innovation, taking advantage of the sale to buy with an attractive assessment. Declared the following in the fourth quarter of 2024 Investor letter:
“Eli Lilly and Company (NYSE: Lly) The actions decreased after the results of the third quarter worse than expected for the medicine segment with weight loss. We started our position of position during the quarter, after the tie and with time for a partial rebound, and our lower average to the weight of the quarter caused a relative contribution.
Usually lly Ranks 3rd In our list of the best growth stocks to buy for the next 3 years. Although we recognize Lly’s growth potential as an investment, our conviction lies in the belief that the AI actions have a great promise to obtain high returns and to do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of Ia more promising than Lly but sells less than five times, see our report on the Ia stock cheap.
